Related Experiment Videos
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells
A Budillon1, P Tagliaferri, M Caraglia
1Cattedra di Oncologia Medica, II Facoltà di Medicina, Università Napoli, Italy.
Abstract:
Unregulated or increased expression of epidermal growth factor receptor (EGF-R) is a common event in neoplastic transformation; modulation of such a receptor by physiological agents could be, therefore, of clinical interest. We have studied the binding ability, the availability at cell surface, and the synthesis of EGF-R in the A431 and KB human epidermoid cancer cell lines after treatment with recombinant alpha-interferon (IFN-alpha). After 48 h of treatment, IFN-alpha induces, in both cell lines, growth inhibition and enhances class I major histocompatibility HLA complex expression, which is a common marker of IFN action. [125I]EGF total binding assessed after 48 h of treatment with IFN-alpha shows a dose-dependent upregulation of EGF-R binding capacity. Saturation plots of the binding data show that IFN-alpha treatment does not dramatically alter the affinity of the EGF-R and indicate that IFN-alpha only increases the number of low affinity receptors. We show that this effect is due to a specific increase in the synthesis of the receptor protein, as assessed by immunoprecipitation of [35S]methionine-labeled cell extracts. Electron microscopy analysis has confirmed an increase of EGF-R proteins at cell surface without major changes in the morphology of the cells. Taken together, these results indicate that IFN-alpha consistently induces both the binding capacity and the synthesis of EGF-R in human epidermoid cancer cells and suggest the use of such a mechanism for new anticancer therapies.
Insights
Recombinant alpha-interferon (IFN-alpha) increases epidermal growth factor receptor (EGF-R) synthesis and binding capacity in human cancer cells. This finding suggests IFN-alpha as a potential therapeutic strategy for cancers driven by EGF-R.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Unregulated epidermal growth factor receptor (EGF-R) expression is common in cancer.
- Modulating EGF-R activity with physiological agents holds clinical potential for cancer therapy.
Purpose of the Study:
- To investigate the effects of recombinant alpha-interferon (IFN-alpha) on EGF-R binding, cell surface availability, and synthesis in human epidermoid cancer cell lines (A431 and KB).
Main Methods:
- Treatment of A431 and KB cells with IFN-alpha.
- Assessment of EGF-R binding using [125I]EGF.
- Analysis of receptor synthesis via immunoprecipitation of [35S]methionine-labeled cell extracts.
- Confirmation of cell surface receptor levels using electron microscopy.
Main Results:
- IFN-alpha induced growth inhibition and enhanced HLA expression in both cell lines.
- A dose-dependent upregulation of EGF-R binding capacity was observed after IFN-alpha treatment.
- IFN-alpha increased the number of low-affinity EGF-R, primarily by enhancing receptor protein synthesis.
- Electron microscopy confirmed increased EGF-R on the cell surface without significant morphological changes.
Conclusions:
- IFN-alpha consistently increases both the binding capacity and synthesis of EGF-R in human epidermoid cancer cells.
- The mechanism suggests a potential role for IFN-alpha in novel anticancer therapies targeting EGF-R.